Ongoing Assessments & Recent Research.
Easy access to our work
Featured News & Insights.
Learn about our latest work.
ICER Publishes Special Report on Treatment for Ulcerative Colitis and Crohn’s Disease as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
This report will be submitted to the Centers for Medicare & Medicaid Services (CMS) as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.
03/03/2026Institute for Clinical and Economic Review Publishes Final Evidence Report on Medication for Smoking Cessation
Independent appraisal committee votes reflect a net health benefit for cytisinicline alone, but uncertainty when compared to varenicline; manufacturer setting a price for cytisinicline to align with value would help ensure public health goals for smoking cessation are met.
02/12/2026Institute for Clinical and Economic Review Releases Evidence Report on Therapies for IgA Nephropathy
All three therapies exhibit net health benefits, but uncertainties remain around the magnitude of long-term improvements in outcomes as well as safety; sibeprenlimab’s price far exceeds usual thresholds for cost-effectiveness
02/09/2026Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Launch Price and Access Report: Drug Approvals from 2022-2024
ICER conducted a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which examines launch pricing for FDA-approved treatments. This report reviewed the affordability and access of the treatments and their value to the overall health system.
Special Assessment to Inform CMS Drug Price Negotiation: Vedolizumab (Entyvio®)
ICER is developing a special report for the Centers for Medicare & Medicaid Services on a therapy for treating Crohn’s disease and ulcerative colitis. This report will be submitted to CMS as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.
Examining Strategies to Ensure Affordable Access for Obesity Medications
ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.
